Toronto, Ontario – September 5, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human cervical carcinoma cell line, ME180.
The American Cancer Society’s estimates for cervical cancer in the United States for 2017 are:
- About 12,820 new cases of invasive cervical cancer will be diagnosed
- About 4,210 women will die from cervical cancer
Cervical cancer was once one of the most common causes of cancer death for American women, but over the last 40 years, the cervical cancer death rate has gone down by more than 50%, due to the increased use of the Pap test.
In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that cervical cancer cells (ME180) were up to 96% destroyed, at an extremely low dose of TLD-1433 (0.1 micromolar), when activated by green laser light (530 nm, 90 J/cm2)
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, supporting a high safety margin in the destruction of cervical cancer cells.
Dr. Kaspler stated that, “The research data collected strongly suggests that TLD-1433 would be effective in the destruction of cervical cancer with high safety margins. I look forward to continuing my research in this promising new cancer indication.”
Dr. Mandel stated that, “I am very pleased that TLD-1433 continues to make strides forward in the destruction of oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. Clinically, in the first 3 patients treated at the Maximum Recommended Starting Dose, we have demonstrated safety and tolerability, pharmacokinetics (the movement and exit of the drug within tissue) and efficacy, when evaluated at 90 days post treatment for Non-Muscle Invasive Bladder Cancer. We have strong preclinical data supporting the use of Rutherrin® (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical cancer.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “The Theralase licenced PDCs have proven to be very strong anti-cancer drugs in initial clinical studies for NMIBC and preclinically for glioblastoma, lung and now cervical cancer. We look forward to successfully expanding the oncological application of our platform of PDCs and the laser light systems that activate them, as we expand clinically into these new oncology targets.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Corporation”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225